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Abstract: While a successful HIV vaccine will likely take several more years to become a 
reality, many anti-retroviral (ARV) drugs are currently available to treat HIV infection, and their 
efﬁ  cacious use has improved the quality of life and life expectancy of millions of HIV-infected 
individuals. A recent addition to these ARVs is a new class of drug that targets the HIV entry 
process by interfering with the action of the CCR5 coreceptor. The ﬁ  rst licensed member of this 
class is a drug called maraviroc, which is also the ﬁ  rst ARV that targets a cellular rather than 
a viral protein. Several other CCR5 antagonists with varied mechanisms of action are being 
developed. Key issues with the use of these drugs include determining their potential for use in 
treatment-naïve versus treatment-experienced patients, the development of sensitive coreceptor 
phenotyping assays to determine patient eligibility, and ﬁ  nally monitoring the emergence of 
resistant viruses and their mechanisms of resistance. This review summarizes the preclinical and 
clinical development of maraviroc as well as studies of HIV resistance to this drug both in vitro 
and in patients. In addition, a range of diverse CCR5 antagonists currently under development, 
are also discussed.
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Introduction
Twenty-ﬁ  ve years after its discovery, the human immunodeﬁ  ciency virus (HIV) and its 
ever-burgeoning prevalence continue to represent a growing worldwide public health 
problem. According to recent estimates, over 33 million people are living with HIV 
all over the world (WHO/UNAIDS 2007). In addition, acquired immunodeﬁ  ciency 
syndrome (AIDS), the disease caused by HIV, is responsible for over 2 million deaths 
per annum.
The use of drug cocktails combining multiple compounds that comprise highly 
active anti-retroviral therapy (HAART) has signiﬁ  cantly improved the quality-of-life 
and life expectancy of millions of HIV-infected individuals. The main components 
of HAART in the past couple decades have been inhibitors of the viral protease and 
reverse-transcriptase enzymes. However, in most patients HIV eventually develops 
resistance to all these drugs. The propensity of the virus for acquiring resistance to any 
given antiviral agent it is faced with, led to the advent of the combination therapies which 
constitute HAART, with the paradigm of using three anti-retrovirals in combination, 
being the current standard of care.
In more recent years, in an effort to target other steps in the virus lifecycle and to 
develop viable treatments for HAART-resistant HIV patients, entry inhibitors have 
emerged as a new target for anti-retroviral (ARV) therapy. HIV mediates its entry 
into target cells using the concerted action of the viral Env protein with a cell surface 
receptor CD4 and a coreceptor (usually chemokine receptors CCR5 or CXCR4). 
Viruses that use the CCR5 or the CXCR4 coreceptors alone are called R5 or X4 viruses 
respectively, while those that can use both are referred to as R5X4 viruses. The Env 
protein exists as a heterotrimer and is comprised of surface gp120 and transmembrane 
gp41 subunits. Receptor binding is mediated by gp120 and fusion by gp41. The entry Drug Design, Development and Therapy 2008:2 152
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process begins with the engagement of the Env trimer on the 
surface of virions by CD4 on the target cell surface. This is 
followed by conformational changes that allow coreceptor 
binding and insertion of the fusion peptide into the target 
cell membrane. Finally the gp41 protein undergoes dramatic 
conformational changes, which serve to bring the viral and 
cellular membranes in close proximity and facilitate mem-
brane fusion.
Entry inhibitors can target the viral entry process, 
described above, at several steps. These include receptor 
binding, coreceptor engagement, and membrane fusion. 
Amongst these candidates the drugs that are farthest along 
in clinical development include the fusion inhibitors and the 
CCR5 coreceptor inhibitors.
Enfuvirtide (Fuzeon®/T-20) is a peptide fusion inhibitor 
that targets a conformational intermediate of the fusion 
process. While enfuvirtide was the only entry inhibitor on 
the market until late 2007, the use of this drug has been 
complicated by its need for twice daily injection, leading to 
some signiﬁ  cant problems with regards to compliance and 
injection site reactions. Owing to these issues, the use of enfu-
virtide has been restricted to treatment-experienced patients 
who are failing HAART, and are on salvage therapy.
CCR5 antagonists are another new class of entry inhibitors 
under development. These inhibitors block the Env: CCR5 
interaction leading to their antiviral effects. Genetic evidence 
provided strong biological rationale for targeting CCR5 in 
the development of new entry inhibitors. A mutation in the 
CCR5 open reading frame results in the premature trunca-
tion and a consequent 32-bp deletion in the protein (CCR5 
Δ32). Although this mutation is relatively common in the 
Caucasian population, with an allele frequency of 15%–20%, 
it was found to be signiﬁ  cantly underrepresented in the HIV-1 
infected groups (Dean et al 1996; Samson et al 1996), and 
individuals homozygous for the mutation are only rarely 
infected with HIV (Biti et al 1997; O’Brien et al 1997; 
Theodorou et al 1997; Michael et al 1998; Gorry et al 2002). 
In fact, in a group of people at high risk, two individuals that 
remained uninfected despite repeated exposure were found 
to be homozygous for the same Δccr5 mutation (Liu et al 
1996). Lymphocytes from these individuals are resistant 
in vitro to R5-using strains but permissive for X4 strains 
of HIV-1 (Paxton et al 1996). In addition, HIV-1 infected 
individuals who are heterozygous for the Δccr5 mutation, 
have around a 2-year delay in their progression to AIDS 
compared with wildtype controls (Dean et al 1996; Huang 
et al 1996; Michael et al 1997; Zimmerman et al 1997). 
Moreover, both heterozygous as well as homozygous carriers 
of the CCR5 Δ32 allele were apparently immunocompetent 
with no obvious abnormalities, suggesting that the absence 
of CCR5 function might not be harmful and that a CCR5 
antagonist should be well tolerated. It should be noted that 
more recently, an association between lack of CCR5 and an 
increased susceptibility to West Nile Virus has been reported 
(Glass et al 2005, 2006), although the mechanistic basis of 
this observation is not understood.
Most recently in October 2007, maraviroc, the ﬁ  rst-
in-class CCR5 antagonist, was licensed by the FDA for use 
in treatment-experienced patients. This review summarizes 
the recent literature on the use of maraviroc in the treatment 
of HIV infection as well as the future of CCR5 inhibitors.
Importance of coreceptor usage 
analysis
Although HIV can use one of two coreceptors CCR5 or 
CXCR4 to mediate entry into target cells, upon transmission 
the majority of newly infected individuals harbor only 
R5-using viruses. In fact 80% of ART therapy-naïve patients 
have only R5-viruses, while 20% have R5X4 and very few 
(1%) have X4 viruses (Brumme et al 2005; Moyle et al 
2005). Due to conﬂ  icting results from different studies, it 
remains unclear if treated patients (with detectable viremia) 
maintain similar rates of R5X4 viral prevalence as treatment-
naïve patients (Moyle et al 2005; Hunt et al 2006). However, 
in highly treatment-experienced patients the prevalence of 
R5X4 viruses has been shown to approach that of R5 viruses 
in at least two studies (Melby et al 2006; Wilkin et al 2007). 
The emergence of X4 using viruses, which usually occurs 
later in disease, has historically been associated with lowered 
CD4 cell counts and more rapid progression to disease (Koot 
et al 1993, 1999; Shankarappa et al 1999). However, it is not 
clear whether the emergence of X4 using strains is a cause 
or an effect of the severe immunodeﬁ  ciency associated with 
disease progression to AIDS.
It has been anticipated that the use of CCR5 antagonists 
can lead to the emergence of CXCR4-using viruses. While 
de novo coreceptor switching is observed less commonly, 
the selection of pre-existing X4 viruses in association with 
the emergence of resistance to CCR5 antagonists has been 
reported in several studies. This highlights the importance 
of accurate and ultrasensitive detection of minority X4-using 
viruses in a patient’s viral quasispecies while determining 
eligibility for CCR5 antagonist therapy.
Interactions between the HIV Env protein and CD4 
lead to the exposure of the coreceptor-binding site, which 
includes the third variable loop (V3) of gp120 as well as the Drug Design, Development and Therapy 2008:2 153
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bridging sheet, a discontinuous epitope that is formed only 
after CD4 engagement. The bridging sheet interacts with the 
N-terminus of CCR5 or CXCR4. The V3 loop, on the other 
hand, mediates interactions with the second extracellular 
loop (ECL2) of CCR5 or CXCR4 and is the principle deter-
minant of coreceptor speciﬁ  city. In fact speciﬁ  c mutations 
affecting the charge in the V3 region have been shown to 
correlate with coreceptor selectivity. For instance, X4 using 
viruses usually have higher net positive V3 charge than R5 
viruses, which is consistent with the fact that CXCR4 has a 
lower net positive charge than CCR5. Therefore in principle, 
env genotypic information should be able to determine the 
coreceptor usage phenotype.
Several methods have been developed for coreceptor usage 
prediction based on V3 region sequence. The simplest of these 
approaches is the 11/25 rule (De Jong et al 1992; Fouchier et al 
1992; Korber et al 1993; Fouchier et al 1995), which predicts 
that a virus is X4 using if there are basic amino acids present 
at positions 11 and 25 of the V3 loop, and R5 using if no basic 
amino acids present at these positions. While this rule is quite 
accurate for R5 viruses, it tends to misclassify many X4 using 
viruses (Jensen et al 2003). Other more sophisticated methods 
for coreceptor usage prediction, including Webcat, WebPSSM, 
and geno2-pheno[coreceptor], have recently been reviewed in 
detail elsewhere (Sierra et al 2007). However, while improve-
ments are being made in this area, the bottomline is that 
none of these methods have a high enough sensitivity and/or 
speciﬁ  city to accurately and consistently predict the tropism 
of a given Env from its V3 genotype.
Due to the lack of better genotypic predictors, at the 
moment phenotypic assays based on cell culture experiments, 
despite their higher cost and slower turnaround time, appear 
to be the most reliable predictors of coreceptor tropism. 
Several such approaches have been developed. These 
include the Troﬁ  le assay (Monogram Biosciences), Tropism 
Recombinant Test (VIRalliance), HIV Phenoscript assay 
(BioAlliance Pharma) and deCIPhR (inPheno Molecular 
Diagnostics) among others. However, the most popular one 
in use at least in the US appears to be the Troﬁ  le assay and 
recently a more sensitive version of this assay called the 
enhanced Troﬁ  le assay has been developed and is being 
used for detection of X4-using viruses at low levels (Reeves 
et al 2007).
Maraviroc: preclinical development
Developed by Pﬁ  zer Global Research and Development, 
maraviroc is the first CCR5 antagonist approved by 
the FDA for use in treatment-experienced patients 
harboring only R5 viruses. The drug was identiﬁ  ed in a 
high-throughput screen designed to select compounds that 
prevented the binding of radiolabeled macrophage inﬂ  am-
matory factor (MIP)-1β, an endogenous chemokine, to the 
CCR5 receptor. The details of the discovery of maraviroc 
have been reviewed elsewhere (Wood and Armour 2005; 
Meanwell and Kadow 2007). Brieﬂ  y, lead optimization 
efforts focused on improving the binding efﬁ  ciency of the 
screening hits and reducing their persistent type 1 CYP2D6 
inhibition as well as the potent hERG cardiac potassium 
channel inhibition liabilities. Eventually, after a lengthy 
optimization process that entailed the synthesis of almost 
1000 compounds, maraviroc was developed. Maraviroc is 
a potent inhibitor of MIP-1β binding to the CCR5 receptor 
(IC50 = 2 nM) and a potent antiviral agent (EC90 = 1 nM 
for inhibition of HIVBAL replication in PM1 cells), while 
its inhibition of the hERG potassium channel is modest 
(Wood and Armour 2005).
Similar to other small molecular CCR5 inhibitors 
(discussed below), the mechanism of action of maraviroc 
is one of allosteric modification. Insertion of these small 
molecules into a cavity located within the transmembrane 
helices disrupts the geometry of a multi-point interaction 
between CCR5 and HIV-1 gp120 (Dragic et al 2000; 
Tsamis et al 2003; Watson et al 2005; Seibert et al 2006). 
This multi-point interaction is formed by binding of the 
second extracellular loop (ECL-2) to elements of the 
gp120 V3 region and the tyrosine-sulfated N-terminus 
(Tyr-Nt) of CCR5 binding the more conserved bridging 
sheet that forms between the C1, C2, and C4 domains 
upon CD4 binding (Cormier and Dragic 2002; Huang 
et al 2007).
In vitro resistance to maraviroc
Antiretroviral drug resistance is a major hurdle in the success 
of long-term HIV therapy. HIV has a propensity for acquiring 
mutations and developing resistance to antiviral drugs owing to 
its high replication rate coupled with the low ﬁ  delity and lack 
of RT proof-reading resulting in a high error rate. Resistance to 
entry inhibitors has been a particularly difﬁ  cult problem since 
these drugs target the env gene, which is the most variable of 
all the HIV genes. Speciﬁ  cally, this diversity in env can lead 
to variable baseline susceptibilities and the pre-existence of 
resistance mutations in patients naïve to these drugs.
For CCR5 inhibitors such as maraviroc, several possible 
mechanisms of resistance can be expected (Figure 1). 
A coreceptor-switching event could occur with R5-using 
viruses switching to using CXCR4 or an alternative Drug Design, Development and Therapy 2008:2 154
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coreceptor, or the emergence of pre-existing X4 viruses. 
Alternatively, viruses could acquire the ability to bind and 
enter using a drug-bound coreceptor. Resistance to CCR5 
inhibitors could also result from viruses that bind coreceptor 
with higher afﬁ  nity (and can therefore compete out bound 
drug), or are able to enter by scavenging low levels of core-
ceptor either due to higher afﬁ  nity or a greater proclivity for 
Env protein triggering.
An in vitro study has shown that maraviroc does not lead to 
a de novo switch to X4-using viruses during serial passaging of 
laboratory-adapted and three of the six CCR5-tropic primary 
isolates studied (Westby et al 2007). However, in the case of 
one virus (SF162) the emergence of pre-existing X4-using 
viruses was reported in this study. For two of the passaged 
primary isolates, maraviroc resistance arose with the mutant 
Envs acquiring an ability to use a drug-bound form of  CCR5. 
This leads to a characteristic “plateau” of maximal inhibition 
in a dose-response curve; in other words, beyond a certain 
maraviroc concentration, increasing drug levels did not inhibit 
virus infection. These plateaus in dose-response have been 
observed for viruses resistant to other coreceptor antagonists, 
suggesting that the recognition of an altered conformation 
of the coreceptor is a common mechanism for escape from 
non-competitive inhibitors of entry (Figure 2B). This is in 
contrast to a competitive mode of  resistance that typically leads 
to clear IC50 shifts in dose-response curves (Figure 2A).
Genotypic changes in resistant viruses are a common 
hallmark of all classes of anti-retrovirals. Typically mutations 
accumulate in a step-wise manner in the gene targeted by a 
drug and either confer resistance or compensate for impaired 
activity resulting from resistance mutations at the drug 
target site. For several antiviral agents, the viral genotype 
is a good measure of phenotype, or the sensitivity of a virus 
to any given drug. Charts containing mutations that are 
known to impart resistance to particular drugs are available 
to physicians, who can create a tailored regimen for each 
patient based on their viral genotype. In this way molecular 
information can be used to guide clinical decisions.
In the case of coreceptor antagonists, the V3 loop of gp120 
is the expected site for resistance mutations since this region 
of the protein is important in mediating the speciﬁ  city of Env-
coreceptor interactions. However, while genotypic changes are 
found in the V3 region of some coreceptor inhibitor-resistant 
viruses, in other cases mutations are also observed in other 
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Figure 1 Potential mechanisms of resistance of HIV to CCR5 antagonists. HIV can become resistant to CCR5 inhibitors in a number of ways.   The virus can adapt to 
scavenge low levels of unbound coreceptors more efﬁ  ciently either by binding coreceptors with higher afﬁ  nity or triggering fusion more quickly (1). HIV could also become 
resistant by competing off drug from coreceptors (2) or by using a drug-bound conformation of the coreceptor (3).   Alternatively, the virus could switch to using CXCR4, 
either via a de novo switch or due to emergence of a pre-existing X4 virus (4), or it could switch to using an alternative coreceptor (5).Drug Design, Development and Therapy 2008:2 155
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regions of both gp120 and gp41 (Trkola et al 2002; Marozsan 
et al 2005; Baba et al 2007; Pugach et al 2007; Westby et al 
2007; Ogert et al 2008). Moreover, for each parental strain 
passaged in the presence of coreceptor inhibitors, different 
resistance-associated changes are observed. Therefore the use 
of viral env genotype as a predictor of resistance to coreceptor 
inhibitors such as maraviroc, might be more complicated 
than for other entry inhibitors such as ENF, where resistance 
mutations usually map to the HR1 region of gp41 which is 
the targeted binding site of ENF.
Maraviroc use in the clinic
Phase 1 and 2 clinical trials
Several phase 1/2a clinical studies have been conducted 
with maraviroc, which all showed signiﬁ  cant reductions in 
HIV viral load in HIV-infected individuals (Fätkenheuer 
et al 2005). In a study that reviewed data from 5 multiple-
dose, phase 1/2a double-blinded, placebo-controlled studies 
of maraviroc, the drug appeared to be well-tolerated in 
10-day monotherapy (Fätkenheuer et al 2004). The most 
adverse effects, which included nausea, rhinitis, dizziness, 
and headache, were moderate. Some subjects on maraviroc 
showed elevations in levels of transaminases or occasional 
elevation in creatinine; however, these effects were not 
considered to be severe. Postural hypotension was the only 
dose-limiting complication that occurred at higher rates than 
placebo in patients receiving a maraviroc dose of 600 mg 
or higher. Encouragingly, 10-day monotherapy studies 
with maraviroc resulted in mean viral load reductions of 
1.6 log10 copies/mL with a dose of 300 mg once daily and 
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Figure 2 Competitive and non-competitive mechanisms of resistance to coreceptor inhibitors. In a competitive mechanism of resistance (A), HIV acquires the ability to 
bind unoccupied coreceptors more efﬁ  ciently, and in this case there is an IC50 shift in a dose response curve relative to a sensitive virus.   Alternatively, in a non-competitive 
mechanism of resistance (B), the virus adapts to enter using a drug-bound conformation of the coreceptor, resulting in a dose-response curve where no further inhibition 
of virus entry occurs beyond a certain drug concentration (“plateau effect”) and no shift in IC50 is observed.Drug Design, Development and Therapy 2008:2 156
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1.84 log10 copies/mL with a dose of 300 mg twice daily. Based 
on these results, phase 2b/3 studies of maraviroc were initiated 
in treatment-experienced and treatment-naïve patients.
Maraviroc use in treatment-experienced 
patients
MOTIVATE-1 and MOTIVATE-2 were randomized, 
double-blind placebo-controlled phase 2b/3 clinical trials 
assessing the safety and efﬁ  ciacy of maraviroc in heavily-
treatment experienced patients with triple-class ARV 
resistance. MOTIVATE-1 included 601 participants from 
the US and Canada, whereas MOTIVATE-2 included 475 
subjects from Europe, Australia and USA. In both studies, 
subjects were randomly assigned to receive maraviroc at 
doses of 300 mg once-daily (qd) or twice-daily (bid), or 
else placebo, in combination with an optimized background 
therapy (OBT) regimen.
Results from 24 weeks of follow-up in both studies 
indicated signiﬁ  cantly better efﬁ  cacy in patients treated with 
maraviroc (qd or bid) + OBT versus placebo + OBT, with 
the virologic response rates being about twice as high in the 
maraviroc arms compared to the placebo arm (Lalezari et al 
2007; Nelson et al 2007). Speciﬁ  cally, mean decreases in 
viral load from baseline were 1.95–1.97 log10 copies/mL in 
the maraviroc bid arms, 1.82–1.95 log10 copies/mL in the 
maraviroc qd arms, and 0.93–1.03 log10 copies/mL in the 
placebo arms. 45.6%–48.5% of patients in the maraviroc bid 
arms, and 40.8%–42.2% in the qd arms achieved viral loads 
below 50 copies/mL, compared with 20.9%–24.6% in the 
placebo arms. Similar trends were observed for viral loads 
below 400 copies/mL, indicating that a higher proportion of 
patients achieved viral loads 50 and 400 copies/mL when 
maraviroc was administered twice instead of once daily. CD4 
cell counts increased from baseline by 102–111 and 107–112 
cells/mm3 in the bid and qd arms, respectively, compared 
with 52–64 cells/mm3 in the placebo arms. While fewer 
patients in the maraviroc arms experienced treatment failure 
compared with placebo, more patients in the maraviroc arm 
experienced a shift in HIV coreceptor usage from CCR5-
tropic to CXCR4-tropic or dual/mixed tropism. Adverse 
event proﬁ  les were similar in both maraviroc arms and the 
placebo arm. Based on these 24-week results, in August 
2007 the Food and Drug Administration (FDA) approved 
maraviroc for use in treatment-experienced patients.
More recently, data from a 48-week combined analysis 
of the MOTIVATE 1 and 2 studies were presented (Hardy 
et al 2008). As seen in the 24-week analysis, maraviroc pro-
duced greater virological response compared with placebo. 
CD4 cell benefits were greater in the maraviroc arms 
(124 cells/mm3 bid, 116 cells/mm3 qd) compared with the 
placebo arm (61 cells/mm3). The pooled analysis revealed no 
new or unique safety ﬁ  ndings beyond the 24-week analysis. 
Discontinuations due to adverse events, serious adverse 
events, and laboratory abnormalities occurred with similar 
frequency in the maraviroc and placebo arms. Therefore, 
treatment with maraviroc appears to provide sustained ARV 
efﬁ  cacy and tolerability in treatment-experienced patients.
Maraviroc use in treatment-naïve patients
Maraviroc in Treatment-naïve Patients (MERIT) is an 
ongoing phase 3 clinical trial designed to compare the 
efficacy and safety of maraviroc 300 mg twice daily 
versus efavirenz 600 mg once daily, each administered 
in combination with fixed-dose zidovudine/lamivudine 
(Combivir®). The study is continuing for 96 weeks; however, 
preliminary analysis from 48-week data were presented 
recently (Saag et al 2007; Heera et al 2008). Twice-daily 
maraviroc was non-inferior to efavirenz in patients with 
vRNA 400 copies/mL (70.6% vs 73.1%) but not in the 
50 copies/mL analysis (65.3% vs 69.3%). In subjects with 
high viral loads (vRNA  100,000 copies/mL) the differ-
ence was even more pronounced in favor of efavirenz, with 
the proportion of subjects with 50 copies/mL on efavirenz 
66.6% and on maraviroc 59.6%. However, maraviroc had a 
superior safety proﬁ  le and a more benign lipid proﬁ  le than 
efavirenz and an overall higher CD4 beneﬁ  t.
In another study aimed at analyzing the virological 
correlates of treatment failure in the MERIT trial, it was 
found that of 721 patients, 24 (3.3%) changed from R5 
at screening to dual/mixed at baseline (Heera et al 2008). 
The virologic response in this group of patients was lower 
both for the efavirenz as well as maraviroc groups, with the 
proportion of subjects with 50 copies/mL being only 54.6% 
and 7.1%, respectively. Moreover, X4 using viruses were 
detected at failure in 10/32 (31.3%) maraviroc patients with 
R5 virus at baseline. Therefore the conclusions from this 
study were that the presence of X4 using viruses at baseline 
is an important predictor of virologic failure on maraviroc. 
Also, similar to treatment-experienced patients, failure due 
to the emergence of X4-using virus is an important, albeit 
infrequently observed, mechanism associated with maraviroc 
failure.
Future of CCR5 inhibition
Besides maraviroc, several promising strategies for CCR5 
blockade are currently being employed in the development Drug Design, Development and Therapy 2008:2 157
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of CCR5 antagonists. These include other small-molecule 
inhibitors, monoclonal antibodies, and genetically derived 
molecules. Modified chemokine derivates (analogs of 
the CCR5 ligand RANTES) are also being developed for 
potential use as microbicides (Kish-Catalone et al 2006; 
Lusso 2006). In general, CCR5 antagonists can be classiﬁ  ed 
into three broad categories (Figure 3). First, small molecule 
inhibitors cause allosteric modiﬁ  cations in CCR5, leading 
to the induction or stabilization of a conformation of CCR5 
that can not be bound by gp120, thereby preventing virus 
entry. Second, monoclonal antibodies sterically block access 
of virus to CCR5. Finally, genetically derived molecules 
(zinc ﬁ  nger nucleases) as well as chemokine analogs induce 
the intracellular trapping of CCR5 to the endoplasmic 
reticulum, preventing CCR5 expression on the surface of 
lymphocytes.
Different types of CCR5 inhibitors have their advan-
tages and disadvantages. For instance, small-molecule 
inhibitors are orally bioavailable, while monoclonal 
antibodies need to be injected intravenously. On the other 
hand, monoclonal antibodies usually have prolonged serum 
half-lives allowing for relatively infrequent administrations, 
whereas orally administered small molecules need more 
frequent dosing to maintain adequate concentrations in the 
face of serum protein binding and active catabolic mecha-
nisms. The therapies discussed below are not intended 
as an exhaustive summary of all CCR5 inhibitors under 
development, but rather a sampling of the same to give the 
reader a ﬂ  avor for the diversity of potential future options 
in this drug class.
Allosteric modulation: small molecule 
inhibitors
Vicriviroc
Vicriviroc is the second most advanced agent in the CCR5 
antagonist class of ARV drugs. Forty-eight week data from 
the Phase II VICTOR-E1 study (Vicriviroc in Combination 
Treatment with Optimized ART Regimen in Experienced 
Subjects) that examined the safety and efﬁ  cacy of vicriviroc 
(30 mg or 20 mg qd) in combination with an optimized 
ritonavir-boosted, protease inhibitor-containing ART 
regimen, were recently presented (Zingman et al 2008). 
Potent and sustained viral suppression was achieved in the 
vicriviroc arms with 1.77 and 1.75 log10 copies/mL mean 
decreases from baseline viral load compared with 0.79 log10 
copies/mL in the control group. Signiﬁ  cantly more patients 
(56%) who added vicriviroc 30 mg once daily to a new OBT 
had fully suppressed HIV-RNA down to 50 copies/mL 
compared with patients on OBT alone (14%). Also mean 
increases from baseline in CD4 cell counts in the vicri-
viroc groups were +102 and +134 cells/mm3, respectively, 
compared with +65 in the control group. Moreover, there 
were no signiﬁ  cant differences in the safety proﬁ  le between 
the vicriviroc and control arms with respect to liver toxicity, 
opportunistic infections, malignancies or other conditions. 
Based on the VICTOR-E1 results, 2 large global phase III 
trials (VICTOR-E3 and VICTOR-E4) are currently enrolling 
approximately 375 treatment-experienced subjects (at more 
than 160 sites worldwide) who will receive 30 mg vicriviroc 
qd in combination with OBT or OBT alone.
Second-generation maraviroc
Following the successful licensing of maraviroc, Pﬁ  zer is 
developing a second-generation CCR5 inhibitor. Their lead 
candidate PF-232798 is an imidazopiperidine CCR5 inhibitor 
that was identified in a medicinal chemistry synthetic 
campaign guided by a biological screening cascade after the 
identiﬁ  cation of the triazole inhibitor maraviroc (Dorr et al 
2008). PF-232798 is a potent oral CCR5 antagonist with 
a primary and selectivity/safety pharmacological proﬁ  le 
similar to maraviroc. It also has broad-spectrum anti-HIV-1 
activity similar to maraviroc. PF-232798 is also active against 
lab-generated maraviroc-resistant CCR5 tropic HIV-1. The 
drug binds to the same pocket as maraviroc within the 
transmembrane region of CCR5, but also shows interactions 
with the ECL2 hinge region. PF-232798 was well tolerated 
in normal volunteers and exhibited more favorable pharma-
cokinetic proﬁ  le than maraviroc, highlighting its potential 
for once-daily dosing.
Steric blockade: monoclonal antibodies
Several antibody-based agents targeting the HIV entry 
process are being developed. For example, TNX-355 targets 
CD4, PRO 542 is aimed at gp120, and PRO 140 and HGS004 
bind CCR5.
PRO 140
PRO 140 is a humanized monoclonal antibody that binds 
to CCR5 without altering its structure or normal function; 
it sterically blocks binding of the coreceptor to virus. 
Interestingly, viral mutants resistant to small-molecule 
inhibitors (derived by in vitro passage), appear to remain 
susceptible to inhibition by PRO 140 (Kuhmann et al 2004; 
Marozsan et al 2005). PRO 140 can also act synergistically 
with maraviroc and vicriviroc to block membrane fusion 
mediated by a primary R5 virus (Murga et al 2006).Drug Design, Development and Therapy 2008:2 158
Ray
PRO 14 was humanized from the original mouse 
monoclonal antibody PA14 and entered phase 1b clinical 
trials in 2007. In this single-dose study, PRO 140 was 
well tolerated at all doses and produced signiﬁ  cant reduc-
tions in viral load and suppressed viral replication for 2–3 
weeks (Progenics). PRO 140 has been granted Fast Track 
designation by the FDA.
HGS004 (CCR5mAb004)
HGS004 is a fully human IgG4 monoclonal antibody against 
CCR5 with robust in vitro activity against several HIV-1 isolates 
(Lalezari et al 2008). A phase I clinical trial examined the safety 
and preliminary antiviral activity of this antibody. This was a 
single-blind, placebo-controlled study that enrolled 63 subjects 
randomized into 5 dosage cohorts (0.4, 2, 8, 20, and 40 mg/kg) 
who received a single intravenous dose of HGS004 or placebo. 
HGS004 was well tolerated even at the highest dose and high-
levels of receptor occupancy were observed for up to 28 days in 
the higher dose cohorts. On day 14, 54% of subjects in the 8-, 
20- and 40-mg/kg groups had plasma HIV-1 RNA reductions 
of  1 log10 copies/mL. In the 40 mg/kg group, 4 of 10 subjects 
had a 1 log10 copies/mL plasma RNA reduction at day 28.
Removal of CCR5 from cell surfaces
Chemokine analogs
The natural ligands of CCR5 have been shown to possess 
anti-HIV activity in vitro (Cocchi et al 1995). Moreover, 
increased expression of the CCR5 ligand, MIP-1a/CCL3, in 
humans (as a result of gene duplication) provides protection 
from HIV acquisition (Gonzalez et al 2005). Chemokine 
analogs can be engineered to enhance their anti-HIV activ-
ity (reviewed in (Hartley and Offord 2005)). Their mecha-
nism of action involves binding of the chemokine receptor 
(eg. CCR5), followed by agonist-induced receptor inter-
nalization, leading to intracellular sequestration (Figure 3). 
While N-terminally modiﬁ  ed chemokine analogs such as 
AOP-RANTES (Simmons et al 1997) and PSC-RANTES 
(Hartley et al 2004) have shown prolonged receptor 
sequestration and potent anti-HIV activity, these protein 
molecules are not orally bioavailable and are likely to have 
poor pharmacokinetics after injection due to aggregation 
on cell surface proteoglycans. However, these factors do 
not preclude the development of these chemokine analogs 
as components of topical microbicides in the prevention of 
HIV transmission (Moore 2005).
Genetic therapies
Several anti-HIV gene therapy approaches, that target HIV 
genes or their products, have also been investigated in the 
past several years (reviewed in [Rossi et al 2007]). These 
genetic-based approaches, such as intrakines (Yang et al 
1997), degrakines (Cofﬁ  eld et al 2003), and zinc-ﬁ  nger 
nucleases (ZFNs), aim to create phenotypic knockouts 
of CCR5.
eg, small molecules 
Steric Blockade
eg, monoclonal Abs
Removal from cell surfac
eg, RANTES analogs, 
genetic approaches
Figure 3 Mechanisms of action of different types of CCR5 inhibitors. Several CCR5 antagonists with diverse modes of action are being developed. In general, there are 
three categories of these inhibitors: those that allosterically modify CCR5 (such as small molecules), those that sterically block viral access to CCR5 (such as monoclonal 
antibodies) and ﬁ  nally those that lead to decreased expression of CCR5 on the cell surface (eg, RANTES analogs and genetic therapies such as ZFNs).Drug Design, Development and Therapy 2008:2 159
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ZFN proteins can be engineered to bind with a high 
degree of speciﬁ  city to particular sequence motifs in the 
genome, and the associated nuclease cleaves the bound DNA 
(Mani et al 2005). Repair of these double-stranded breaks is 
associated with the introduction of high frequency deletions 
and insertions at the cleavage site. CCR5-ZFN proteins have 
been developed and their administration to T-cell lines and 
primary human CD4+ T-cells resulted in a population of 
CCR5-modiﬁ  ed HIV-resistant cells (Perez et al 2008). ZFN-
modiﬁ  ed T-cell lines expanded in culture in the presence of 
HIV, and comprised the majority of cells in the population 
after 70 days. Genetic disruption of CCR5 imparted robust, 
stable, and heritable protection against HIV-1 in a NOG/SCID 
mouse model of infection (Perez et al 2008). The eventual 
clinical goal is to use these CCR5-ZFNs to perform ex vivo 
gene therapy on T cells from HIV-infected individuals and 
generate a reservoir of permanently HIV-resistant T cells that 
can be engrafted back into patients by reinfusion. Therefore, 
the fact that HIV-infected mice engrafted with ZFN-modiﬁ  ed 
CD4+ T cells had lower viral loads and higher CD4+ T cell 
count than mice engrafted with wild-type CD4+ T cells, in this 
study, holds promise for the potential to reconstitute immune 
function in individuals with HIV/AIDS by maintenance of 
an HIV-resistant CD4+ T-cell population.
Conclusion
Maraviroc is a valuable addition to the arsenal of ARV drugs 
available in the combat against HIV and AIDS. It heralds 
a new class of ARV drugs, namely CCR5 inhibitors, with 
several other second-generation candidates following in 
the clinical pipeline. While they comprise a promising new 
approach in controlling HIV infection, CCR5 inhibitors 
come with their share of problems and important caveats 
that should be kept in mind for ensuring their successful 
use. One of the greatest hurdles in the success of this class of 
drugs is the need to phenotype the patients’ viral quasispecies 
and sensitive detection of very low level CXCR4 usage, to 
prevent treatment of ineligible patients. In the coming years, 
more sophisticated coreceptor usage prediction programs 
as well as phenotypic assays with higher sensitivities are 
required to overcome this problem.
Resistance is another hurdle that inevitably rears its ugly 
head in the use of any ARV drug. Coreceptor inhibitors are 
no exception to this rule. One of the most feared predicted 
mechanism of resistance to CCR5 inhibitors was a de novo 
switch to X4-using viruses, which are associated with late-
stage disease. However, results from most resistance studies, 
thus far, suggest that this switch to CXCR4 usage is in fact 
not observed frequently and instead viruses usually acquire 
resistance to these drugs by using a drug-bound conformation 
of the CCR5 coreceptor.
Another key issue in the optimal administration of CCR5 
antagonists, such as maraviroc, is which patient should 
receive these drugs: treatment-experienced or treatment-
naïve patients? On the one hand, the use of new ARV drugs 
ﬁ  nds favor with physicians in a salvage regimen administered 
to multi-class resistant treatment-experienced patients. In fact 
this is the current recommendation for the use of maraviroc. 
However, in the case of CCR5 inhibitors the percentage of 
patients harboring R5 only using viruses is much higher 
in treatment-naïve patients (about 80% in naïve versus 
48%–60% in experienced patients), arguing for a more favor-
able target population in these rather than more experienced 
subjects. Moreover, maraviroc’s new mechanism of action 
may result in a reduction in the number of latently infected 
cells, and add to its promise as a candidate for ﬁ  rst line 
therapy. While there is no doubt in the beneﬁ  t that treatment-
experienced patients (with R5 viruses) can derive from using 
maraviroc (MOTIVATE trial results), recent clinical data 
from treatment-naïve patients (MERIT trial) can potentially 
revitalize interest in CCR5 antagonists as a treatment option 
for treatment-naïve patients especially since despite its lack 
of non-inferiority in patients reaching viral loads below 
50 copies/mL, maraviroc had a superior safety proﬁ  le and 
greater CD4 beneﬁ  t compared to efavirenz.
Since CCR5 antagonists such as maraviroc target a cel-
lular instead of viral protein (as do all other ARVs), another 
point to consider in the prescription of these drugs is whether 
they should be used in addition to triple therapy or as a 
replacement for one drug of triple therapy. Further studies 
into the different combinations of maraviroc with existing 
ARV regimens are required to address this question.
In conclusion, with the advent of maraviroc, an exciting 
new class of drugs has entered the arena of ARV therapy. 
Several key issues and questions regarding its optimal use and 
application remain unanswered, and should be addressed in 
upcoming clinical trials. Moreover, in the years to come, we can 
look forward to several other CCR5 antagonists with diverse 
mechanisms of action becoming available to patients.
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